Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Preferred Shares (2017 - 2020)

Protara Therapeutics' Preferred Shares history spans 4 years, with the latest figure at $8.0 for Q3 2020.

  • Quarterly Preferred Shares fell 100.0% to $8.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $8.0 through Sep 2020, down 100.0% year-over-year, with the annual reading at $18.5 million for FY2019, 14.22% down from the prior year.
  • Preferred Shares came in at $8.0 for Q3 2020, up from $4.0 in the prior quarter.
  • In the past five years, Preferred Shares ranged from a high of $21.5 million in Q4 2017 to a low of $4.0 in Q1 2020.
  • The 4-year median for Preferred Shares is $21.2 million (2019), against an average of $14.7 million.
  • Year-over-year, Preferred Shares changed 0.0% in 2018 and then plummeted 100.0% in 2020.
  • Protara Therapeutics' Preferred Shares stood at $21.5 million in 2017, then changed by 0.0% to $21.5 million in 2018, then dropped by 14.22% to $18.5 million in 2019, then plummeted by 100.0% to $8.0 in 2020.
  • Per Business Quant, the three most recent readings for TARA's Preferred Shares are $8.0 (Q3 2020), $4.0 (Q2 2020), and $4.0 (Q1 2020).